|
| 36672433 | Pyruvate Dehydrogenase Inhibition Leads to Decreased Glycolysis, Increased Reliance on Gluconeogenesis and Alternative Sources of Acetyl-CoA in Acute Myeloid Leukemia. | Cancers (Basel) | 2023 |
| 37454532 | Assessment of an embedded primary care-derived electronic health record (EHR) frailty index (eFI) in older adults with acute myeloid leukemia. | J Geriatr Oncol | 2023 |
| 37341164 | Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients. | J Surg Oncol | 2023 |
| 36856803 | Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen. | Ann Hematol | 2023 |
| 35321842 | Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML). | Cancer Lett | 2022 |
| 35668193 | P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. | Nat Cancer | 2022 |
| 35487616 | Tailoring a physical activity intervention to older adults receiving intensive chemotherapy for acute myeloid leukemia (AML): One size does not fit all. | J Geriatr Oncol | 2022 |
| 35354808 | Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. | Nat Commun | 2022 |
| 35037026 | hDirect-MAP: projection-free single-cell modeling of response to checkpoint immunotherapy. | Brief Bioinform | 2022 |
| 34695644 | Re-induction therapy in adult patients with acute myeloid leukemia with ⿤20 % blasts: A retrospective cohort study. | Leuk Res | 2021 |
| 33643502 | A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. | J Hematol | 2021 |
| 33640708 | Efficacy of 10-day decitabine in acute myeloid leukemia. | Leuk Res | 2021 |
| 30962090 | Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. | J Geriatr Oncol | 2020 |
| 32049445 | The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study. | Cancer Med | 2020 |
| 32092139 | Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. | Blood Adv | 2020 |
| 32733012 | Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. | Leukemia | 2020 |
| 32698198 | Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. | Blood | 2020 |
| 32428837 | The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. | Transl Oncol | 2020 |
| 30554278 | Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. | Support Care Cancer | 2019 |
| 31665578 | Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML. | N Engl J Med | 2019 |
| 31512500 | Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. | Future Oncol | 2019 |
| 31512497 | A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. | Future Oncol | 2019 |
| 30773463 | Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. | Cell Metab | 2019 |
| 29437791 | A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. | Clin Cancer Res | 2018 |
| 29807044 | Mitochondria in cancer metabolism, an organelle whose time has come? | Biochim Biophys Acta Rev Cancer | 2018 |
| 27881872 | In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells. | Leukemia | 2017 |
| 28495639 | Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. | Lancet Oncol | 2017 |
| 28985622 | Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. | Leuk Res | 2017 |
| 28644853 | The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. | PLoS One | 2017 |
| 26829896 | Improving nucleoside analogs via lipid conjugation: Is fatter any better? | Crit Rev Oncol Hematol | 2016 |
| 26527394 | Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). | J Geriatr Oncol | 2016 |
| 27732654 | A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. | PLoS One | 2016 |
| 27627675 | Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. | J Am Geriatr Soc | 2016 |
| 27279153 | The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. | Future Oncol | 2016 |
| 25563333 | Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia. | J Clin Pathol | 2015 |
| 26154683 | High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. | Leuk Res | 2015 |
| 25510486 | Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. | Leuk Res | 2015 |
| 24149914 | Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). | Ann Hematol | 2014 |
| 25402485 | The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. | PLoS One | 2014 |
| 25071138 | Acute myeloid leukemia and myelodysplastic syndromes in older adults. | J Clin Oncol | 2014 |
| 25127690 | The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). | Leuk Res | 2014 |
| 25165100 | A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. | Clin Cancer Res | 2014 |
| 24961587 | The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. | Oncotarget | 2014 |
| 23131583 | Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. | Leuk Res | 2013 |
| 23550038 | Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. | Blood | 2013 |
| 23085462 | Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. | Exp Hematol | 2013 |
| 23081702 | Animal models of leukemia: any closer to the real thing? | Cancer Metastasis Rev | 2013 |
| 22362039 | Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. | Blood | 2012 |
| 22905229 | Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. | PLoS One | 2012 |
| 21288478 | Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. | Exp Hematol | 2011 |